Semaglutide Reverses Key Aging Markers and Extends Lifespan in Landmark Mouse Study

Semaglutide, the active ingredient in widely used GLP-1 receptor agonists such as Ozempic and Wegovy, may offer benefits beyond appetite suppression and glycemic control. According to a National Institutes of Health (NIH)-funded study, the drug mitigated several detrimental effects of aging and extended the lifespan of older, healthy mice.

Researchers at the University of California, Berkeley directly compared semaglutide with calorie restriction, one of the most established interventions for extending lifespan in laboratory animals. While the drug replicated many of the anti-aging effects associated with reduced food intake, it surpassed these benefits in several key areas.

These findings suggest that GLP-1 receptor agonists may directly influence the biological aging process. Previous animal research has demonstrated that these drugs can delay the onset of various age-related pathologies. If semaglutide targets core mechanisms of aging, it could explain the broad spectrum of health benefits observed across diverse clinical conditions.

“Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see,” noted Rafael de Cabo, Ph.D., a senior investigator at the NIH’s National Institute on Aging (NIA), who authored a commentary accompanying the study.

Testing Semaglutide Late in Life

To evaluate the drug’s potential when aging is already advanced, a research team led by Danica Chen, Ph.D., administered semaglutide to 20-month-old female mice over a three-month period.

Compared to untreated controls, the treated mice exhibited superior muscle and cognitive function. Additionally, gene expression analysis revealed improvements in key hallmarks of aging, including reduced inflammation and enhanced cellular repair and regenerative capacity.

The lifespan results were particularly notable. In a separate cohort treated continuously with semaglutide until natural death, the median lifespan was extended by nearly 100 days compared to untreated mice.

Was Eating Less the Real Reason?

Since semaglutide is known to suppress appetite, the researchers sought to determine whether the observed anti-aging effects were merely a secondary result of reduced caloric intake.

To investigate, they directly compared semaglutide with calorie restriction. For five months, one group of 20-month-old female mice received semaglutide, while another was subjected to a 24% calorie-restricted diet matched to the food intake of the treated group.

Both interventions yielded many similar physiological outcomes. However, semaglutide demonstrated distinct advantages in critical areas. Treated mice showed improvements beyond their baseline in exploratory behavior, spatial memory, and glycemic regulation. Furthermore, their metabolic rate remained stable, whereas calorie-restricted animals experienced a metabolic slowdown.

These findings indicate that semaglutide’s anti-aging benefits extend beyond simply mimicking the effects of a reduced-calorie diet.

“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction. Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions,” explained Chen, corresponding author of the study and professor of metabolic biology and nutrition at UC Berkeley.

Could GLP-1 Drugs Affect Human Aging?

While these findings open promising new avenues for longevity research, they do not demonstrate that Ozempic, Wegovy, or other GLP-1 drugs can extend human lifespan.

Substantial clinical research will be required to determine if these anti-aging effects translate to humans. For instance, a recent post-hoc analysis of the SLIM LIVER trial offers preliminary insights, but further studies are essential to establish whether GLP-1 therapies can meaningfully influence human aging or longevity.

Chen noted that future clinical trials may investigate these therapies in healthy older adults. If similar benefits are confirmed in individuals without obesity or diabetes, the clinical applications of GLP-1 treatments could expand significantly.

This research was supported by the NIH through NIA grants R01AG063404, R01AG063389, and R01AG082105.

Source link